Literature DB >> 3495545

Behavioral activation and the variability of cerebral glucose metabolic measurements.

R Duara, K Gross-Glenn, W W Barker, J Y Chang, A Apicella, D Loewenstein, T Boothe.   

Abstract

Variability in cerebral glucose metabolism was examined between and within subjects when paired studies were performed in the resting state or in a behaviorally activated state. Both normal and demented subjects were studied twice each, from 1 to 6 weeks apart, under near-identical conditions, using positron emission tomography (PET) and [18F]fluorodeoxyglucose. Resting state studies were repeated in nine normal and four demented subjects. A picture-viewing test, used for activation during PET, was used repeatedly in seven normal and five demented subjects. Within-subject variability, as assessed by the percent difference in metabolic rates in paired studies, was reduced by 60-70% for activation state compared to resting state studies in normals. It is concluded that PET studies of brain metabolism, which are designed to study the active brain, should indeed be performed in functionally activated states, as in addition to demonstrating metabolism during a defined functional state, activation studies show reduced variability of cerebral metabolic measures.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3495545     DOI: 10.1038/jcbfm.1987.62

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  13 in total

1.  Six-month test-retest reliability of MRI-defined PET measures of regional cerebral glucose metabolic rate in selected subcortical structures.

Authors:  S M Schaefer; H C Abercrombie; K A Lindgren; C L Larson; R T Ward; T R Oakes; J E Holden; S B Perlman; P A Turski; R J Davidson
Journal:  Hum Brain Mapp       Date:  2000-05       Impact factor: 5.038

2.  Global and regional cerebral metabolic rate of 2-[18F]fluoro-2-deoxy-D-glucose in the presence of ofloxacin, a gamma-aminobutyric acid a receptor antagonist.

Authors:  E E Camargo; S Sostre; B Sadzot; I Shafique; Z Szabo; J M Links; R F Dannals; H N Wagner
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 3.  Some problems for representations of brain organization based on activation in functional imaging.

Authors:  John J Sidtis
Journal:  Brain Lang       Date:  2006-08-30       Impact factor: 2.381

4.  Factor analysis of regional cerebral glucose metabolic rates in healthy men.

Authors:  Z Szabo; E E Camargo; S Sostre; I Shafique; B Sadzot; J M Links; R F Dannals; H N Wagner
Journal:  Eur J Nucl Med       Date:  1992

5.  Lateralisation of cortical function during cognitive tasks: regional cerebral blood flow studies of normal individuals and patients with schizophrenia.

Authors:  K F Berman; D R Weinberger
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-02       Impact factor: 10.154

Review 6.  Increased regional cerebral glucose metabolism and semantic memory performance in Alzheimer's disease: a pilot double blind transdermal nicotine positron emission tomography study.

Authors:  R W Parks; R E Becker; R F Rippey; D G Gilbert; J R Matthews; E Kabatay; C S Young; C Vohs; V Danz; P Keim; G T Collins; S S Zigler; P G Urycki
Journal:  Neuropsychol Rev       Date:  1996-06       Impact factor: 7.444

7.  Reproducibility of cerebral glucose utilization measured by PET and the [18F]-2-fluoro-2-deoxy-d-glucose method in resting, healthy human subjects.

Authors:  P Maquet; D Dive; E Salmon; R von Frenckel; G Franck
Journal:  Eur J Nucl Med       Date:  1990

8.  Decreased cerebral glucose metabolism associated with mental deterioration in multi-infarct dementia.

Authors:  K Meguro; C Doi; M Ueda; T Yamaguchi; H Matsui; S Kinomura; M Itoh; K Yamada; H Sasaki
Journal:  Neuroradiology       Date:  1991       Impact factor: 2.804

9.  Distributed neural actions of anti-parkinsonian therapies as revealed by PET.

Authors:  I K Goerendt; A D Lawrence; M A Mehta; J S Stern; P Odin; D J Brooks
Journal:  J Neural Transm (Vienna)       Date:  2005-07-29       Impact factor: 3.575

Review 10.  Imaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology?

Authors:  Emilio Merlo Pich; Andreas Jeromin; Giovanni B Frisoni; Derek Hill; Andrew Lockhart; Mark E Schmidt; Martin R Turner; Stefania Mondello; William Z Potter
Journal:  Alzheimers Res Ther       Date:  2014-07-30       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.